Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Longboard Pharmaceuticals, Inc. (LBPH)
Company Research
Source: Yahoo! Finance
Presented late-breaking data for bexicaserin from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting in April 2024 Bexicaserin global Phase 3 program expected to initiate by YE 2024 LP659 first-in-human Phase 1 single-ascending dose (SAD) study topline data expected Q2 2024 Ended first quarter 2024 with $321.0 million in cash, cash equivalents and investments; cash runway is expected to support current planned operations into 2027 LA JOLLA, Calif., May 02, 2024 BUSINESS WIRE Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results. "I am extremely encouraged by the totality of the bexicaserin data generated to date. The recently presented late-breaking data from the PACIFIC Study at AAN continues to support the potential of bexicaserin as a best-in-class
Show less
Read more
Impact Snapshot
Event Time:
LBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBPH alerts
High impacting Longboard Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LBPH
News
- Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions [Yahoo! Finance]Yahoo! Finance
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
- Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $60.00 price target on the stock.MarketBeat
LBPH
Earnings
- 11/2/23 - Beat
LBPH
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/15/24 - Form 8-K
- LBPH's page on the SEC website